top of page

Our Business Model

Learn about how we do business at Ryniant. 

AI Driven. Decentralized.

Ryniant Sciences is a nonprofit biotech organization dedicated to transforming global healthcare through cutting-edge AI innovation and accessible science. At the heart of our model is the Ominor Platform — an AI-powered system that integrates genomic, epigenomic, and clinical data to accelerate the development of targeted therapies and tools for global health.

Hub-and-Spoke Subsidiary Structure

We operate using a decentralized, modular structure built around field-specific research and development arms — our subsidiaries. Each is empowered to pursue a specific health domain or innovation stream while remaining connected through the central Ominor Platform.

​

Our subsidiaries include:

  • Neurological Research Division – tackling neurodegenerative and rare brain disorders

  • Rare & Neglected Disease Division – focusing on underserved global illnesses

  • Dermatology Division – advancing therapies for genetic and inflammatory skin conditions

  • Bluvia – our public health unit focused on AI-driven population health solutions

  • Calrivis – our health informatics division building intelligent biomedical data tools

​

​

Each unit functions semi-autonomously to allow for innovation speed, local partnerships, and agile focus — all while leveraging the shared data and tools of the Ominor core.

Reclaiming and Reviving Abandoned Research

Ryniant identifies shelved drug candidates, unused academic research, and under-leveraged datasets — especially in underserved communities — and brings them back to life using our advanced AI tools. By doing this, we reduce waste in the global R&D pipeline while creating new possibilities for treatments.

Ominor: The AI Engine Behind It All

Our proprietary Ominor Platform serves as the central intelligence system for all subsidiaries. It:

​

  • Screens drug candidates with unmatched precision

  • Integrates multi-omics, genomic, and clinical data

  • Simulates clinical trials with digital twins

  • Drives decision-making across all development stages

​

Every research initiative we pursue is powered by this scalable, intelligent backbone.

Strategic Partnerships for Social Impact

As a 501(c)(3), we collaborate with public and private organizations to deliver results, not just revenue. Our current partners include:

​

  • Microsoft & Google – providing cloud, AI, and research support

  • SEWA International – supporting global STEM and outreach efforts

  • Academic collaborators from MIT, Cornell, and Arizona State University

​​

These partnerships ensure we stay mission-aligned while scaling our impact.

Capital Efficiency Through Modular Growth

We use a modular risk approach — each division can pursue its own funding, partnerships, and strategy without risking the broader organization. Our capital is directed toward:

​

  • Building the Ominor Platform

  • Expanding our infrastructure

  • Developing applications like Bluvia Alpha and Calrivis Z1

  • Securing patents and supporting global science education

​​

We pursue grants, venture philanthropy, and mission-aligned investment, not traditional VC, to maintain our commitment to open, ethical science.

bottom of page